Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Common Equity (2022 - 2025)

Historic Common Equity for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $343.5 million.

  • Praxis Precision Medicines' Common Equity fell 1023.37% to $343.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.5 million, marking a year-over-year decrease of 1023.37%. This contributed to the annual value of $445.4 million for FY2024, which is 53938.05% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Common Equity of $343.5 million as of Q3 2025, which was down 1023.37% from $404.2 million recorded in Q2 2025.
  • Praxis Precision Medicines' Common Equity's 5-year high stood at $445.4 million during Q4 2024, with a 5-year trough of $64.5 million in Q1 2023.
  • Moreover, its 4-year median value for Common Equity was $191.0 million (2022), whereas its average is $233.4 million.
  • Per our database at Business Quant, Praxis Precision Medicines' Common Equity tumbled by 6625.1% in 2023 and then surged by 53938.05% in 2024.
  • Over the past 4 years, Praxis Precision Medicines' Common Equity (Quarter) stood at $76.1 million in 2022, then fell by 8.46% to $69.7 million in 2023, then soared by 539.38% to $445.4 million in 2024, then fell by 22.89% to $343.5 million in 2025.
  • Its last three reported values are $343.5 million in Q3 2025, $404.2 million for Q2 2025, and $439.2 million during Q1 2025.